title: Toll-like receptor 2 and 4 combination engagement upregulate IL-15 synergistically in human rheumatoid synovial fibroblasts.
abstract: Toll-like receptors (TLRs) are pattern-recognition receptors that connect innate and adaptive immunity. Interleukin-15 (IL-15) is a proinflammatory, innate response cytokine that mediates pleiotropic effector functions in inflammatory synovitis of rheumatoid arthritis (RA). The aim of this study was to clarify whether stimulation of TLR2 and TLR4 by their specific ligands induces the production of IL-15 in fibroblast-like synoviocytes (FLS) from RA patients. FLS were isolated from RA synovial tissues and stimulated with the TLR2 ligand bacterial peptidoglycan (PGN) and the TLR4 ligand lipopolysaccharide (LPS). IL-15 in the culture supernatants was measured by ELISA, and mRNA levels were assessed by RT-PCR and real time PCR. The expression of TLR2, TLR4, and IL-15 in the RA synovium was quantified by immunohistochemistry and compared with values obtained in osteoarthritis synovium. IL-15 production increased in culture supernatants of RA FLS stimulated with PGN or PGN plus LPS, and this was upregulated at the transcriptional level. In contrast, LPS did not increase the level of IL-15 although it augmented the stimulatory effect of PGN on IL-15 production. Inhibition of nuclear factor (NF)-kappaB with a specific inhibitor abrogated the stimulatory effect of PGN or PGN plus LPS on IL-15. Neutralization of TLR2 with a blocking monoclonal antibody significantly reduced IL-15 production (P<0.05), reflecting the functional relevance of TLR2 activation in the induction of IL-15 production. These data suggest that TLR2 activation in RA FLS by microbial constituents is involved in the induction of IL-15 and that TLR2 promotes inflammation through NF-kappaB. TLR4 augmented the stimulatory effect of TLR2 on IL-15, possibly contributing to the maintenance of synovitis in patients with RA.
authors.affiliation: Department of Internal Medicine, Division of Rheumatology, Hallym University Kang-Nam Sacred Heart Hospital, Seoul, Republic of Korea.
authors.forename: Young Ok
authors.initials: YO
authors.lastname: Jung
authors.forename: Mi-La
authors.initials: ML
authors.lastname: Cho
authors.forename: Chang-Min
authors.initials: CM
authors.lastname: Kang
authors.forename: Joo-Yeon
authors.initials: JY
authors.lastname: Jhun
authors.forename: Jin-Sil
authors.initials: JS
authors.lastname: Park
authors.forename: Hye-Joa
authors.initials: HJ
authors.lastname: Oh
authors.forename: Jun-Ki
authors.initials: JK
authors.lastname: Min
authors.forename: Sung-Hwan
authors.initials: SH
authors.lastname: Park
authors.forename: Ho-Youn
authors.initials: HY
authors.lastname: Kim
mesh_terms: D000906:Antibodies / Q000276:immunology / Q000494:pharmacology; D001172:Arthritis, Rheumatoid / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D005347:Fibroblasts / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D006801:Humans; D019409:Interleukin-15 / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D012717:Sesquiterpenes / Q000494:pharmacology; D013583:Synovial Membrane / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D051195:Toll-Like Receptor 2 / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000276:immunology* / Q000378:metabolism; D051197:Toll-Like Receptor 4 / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000276:immunology* / Q000378:metabolism; D015854:Up-Regulation
chemical_list: D000906:Antibodies; D019409:Interleukin-15; D016328:NF-kappa B; D012717:Sesquiterpenes; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; C002669:parthenolide